Lyme Disease Vaccine for Humans: Why LYMErix Failed—and What’s Next
A Lyme vaccine once existed.
It helped prevent the rash.
But did it prevent the disease?
Lyme disease vaccine for humans remains one of the most searched—and debated—topics in Lyme disease prevention.
This question is becoming increasingly relevant as new vaccines move closer to approval.
LYMErix, the first Lyme disease vaccine for humans, was approved in 1998 and withdrawn just four years later.
Not because the science failed—but because public trust did.
As new Lyme vaccines move through clinical trials, that history still matters.
Is There a Lyme Disease Vaccine for Humans?
No, there is currently no Lyme disease vaccine for humans available.
LYMErix, the only previously approved Lyme vaccine, was withdrawn from the market in 2002.
New Lyme vaccines are currently in clinical trials but are not yet available for public use.
This reflects a broader challenge in preventing Lyme disease and its long-term complications.
Start here: Lyme disease prevention
What Was LYMErix and How Did It Work?
How did the vaccine prevent Lyme disease?
LYMErix targeted OspA (outer surface protein A), a protein found on Borrelia burgdorferi, the bacteria that causes Lyme disease.
Its mechanism was unusual.
Instead of acting only within the human body, the vaccine stimulated antibodies that worked inside the tick—killing the bacteria before transmission could occur.
Clinical trials showed the vaccine was partially effective:
- About 76% effectiveness after three doses
- Approximately 50% effectiveness after two doses
- Strong protection against erythema migrans (the Lyme rash)
However, an important question remains.
While LYMErix reduced the risk of erythema migrans, its ability to prevent later manifestations of Lyme disease was less clear.
This includes complications affecting the nervous system, heart, or joints.
Understanding this distinction is critical when evaluating the real-world impact of a Lyme disease vaccine.
Why Was LYMErix Withdrawn?
What led to its disappearance?
Several factors likely contributed to its decline.
- Limited effectiveness beyond early disease
- A multi-dose schedule over time
- Cost considerations
- Public concerns about safety
Concerns emerged about a possible autoimmune reaction related to the OspA protein.
These concerns were never conclusively proven—but they shaped public perception.
At the same time, broader vaccine skepticism was increasing.
Demand fell sharply, and the manufacturer voluntarily withdrew the vaccine in 2002.
The experience with LYMErix continues to influence how new Lyme vaccines are viewed today.
Will People Accept a New Lyme Vaccine?
What do recent surveys suggest?
In a survey of 1,015 adults in the United States, individuals living in the Northeast—where Lyme disease is most common—were more likely to consider vaccination.
However, people with lower trust in public health institutions were less likely to express interest.
This highlights an important reality: acceptance depends on trust, not just effectiveness.
Survey responses may not predict real-world behavior.
What Questions Still Matter for New Vaccines?
What should patients and clinicians be asking?
- Will the vaccine prevent more than just the initial rash?
- Will it reduce the risk of post-treatment Lyme disease syndrome (PTLDS)?
- How durable is the protection?
- Are safety concerns fully addressed?
These questions reflect a broader challenge in preventing Lyme disease and its long-term complications.
Frequently Asked Questions
Why was the LYMErix Lyme disease vaccine pulled from the market?
LYMErix was withdrawn in 2002 due to low demand. Contributing factors included safety concerns, a multi-dose schedule, cost, and declining public trust.
Will a new Lyme vaccine prevent chronic Lyme disease?
This remains uncertain. LYMErix reduced early infection in many patients, but its ability to prevent persistent symptoms was not clearly established.
Was LYMErix safe?
Available data did not confirm a causal link between the vaccine and autoimmune arthritis. However, concerns about safety contributed to reduced public confidence.
Clinical Perspective
Preventing early Lyme disease is important—but may not fully address the risk of later complications.
This raises an important clinical question: does preventing the rash prevent the disease?
Future vaccines will need to demonstrate protection not only against early infection—but also against the broader spectrum of Lyme disease.
Clinical Takeaway
LYMErix demonstrated that a Lyme disease vaccine is possible—but also revealed important limitations.
Future vaccines will need to address both effectiveness and confidence.
If a new Lyme vaccine becomes available, its success will depend not only on efficacy—but also on trust.
Related Reading
References
- Motta M. Could concern about climate change increase demand for a Lyme disease vaccine in the U.S.? Vaccine. 2020.
- Steere AC, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A. N Engl J Med. 1998.
- Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. Epidemiol Infect. 2007.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
I would love to see a vaccine for those who are already suffering immensely from this horrible disease. People are not going to take a vaccine to prevent something that most people don’t understand. The only people who understand this disease are those who have been suffering for many years. I’m 62 and have had it for 32 years. I had 6 attachments. All filled on my pillow. I remember it well. But dismissed it because Lyme disease was not even being talked about. This is a neurological mess. My life is pretty much over.
Some people were required to get the previous vaccine because they had outdoor occupations. They had no choice.
Also, there was documented, published damage from that vaccine. In fact, current makers of lyme vaccines have said they removed those elements that caused an autoimmune condition. That is the opposite of the claims that anti-vaxxers and false claims were to blame.
I was vaccine participant in 1995 LD from SmithKline Beecham. I almost died, the study docs denied my symptoms after 3 shots, lab changed ownership & became GlaGlaxoSmithKline etc… Its all for $ not facts! I still suffer daily, lost my marriage, my home & continue to suffer! DON’T GET LD VACCINE!
Yes, it’s terrible what people who have Lyme disease go through with no proper testing.
Why would I want a vaccine if I already have it?
CDC has to get on board all the way.
No ! I do not trust lyme vaccine. I got the lymerix and now I have chronic lyme. How can you make a vaccine when there are so many strains ? This would not protect against coinfections either giving people a false sense of protection. It would also allow doctors to dismiss sick people.
Could you share your story in the Lyme disease and COVID-19 survey if you have not already done so. The link is https://danielcameronmd.com/lyme-disease-covid-survey/